C.	Whittaker	et	al

# 1 Factors associated with variation in single-dose albendazole

## 2 pharmacokinetics: A systematic review and modelling analysis

## 3 Short title: Review and modelling of albendazole pharmacokinetics

- 4 Charles Whittaker<sup>1,5,§</sup>, Cédric B. Chesnais<sup>2</sup>, Sébastien D.S. Pion<sup>2</sup>, Joseph Kamgno<sup>3</sup>, Martin
- 5 Walker<sup>4,5</sup>, Maria-Gloria Basáñez<sup>1,5</sup>\* & Michel Boussinesq<sup>2</sup>\*
- <sup>1</sup>MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease
- 7 Epidemiology, School of Public Health, Imperial College London, London, UK
- 8 <sup>2</sup> Institut de Recherche pour le Développement (IRD), Montpellier, France
- 9 <sup>3</sup>Centre for Research on Filariasis & other Tropical Diseases, and Faculty of Medicine and
- 10 Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
- <sup>4</sup>Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, UK
- <sup>5</sup>London Centre for Neglected Tropical Disease Research, Department of Infectious Disease
- 13 Epidemiology, School of Public Health, Imperial College London, London, UK
- 14 \* Joint senior authors
- 15 <sup>§</sup>Corresponding author: <u>charles.whittaker16@imperial.ac.uk</u>

#### C. Whittaker et al.

#### Albendazole Pharmacokinetics 2

## 17 Abstract

## 18 Background

Albendazole is an orally administered anti-parasitic medication with widespread usage in a variety of both programmatic and clinical contexts. Previous work has shown the drug to be characterised by significant inter-individual pharmacokinetic variation. This variation is thought to have important consequences for treatment success, but current understanding of the factors associated with this variation remains incomplete.

## 24 Methodology/Principal Findings

25 We carried out a systematic review to identify references containing temporally 26 disaggregated data on the blood concentration of albendazole and/or (its pharmacologically-27 active metabolite) albendazole sulfoxide following a single oral dose. These data were then integrated into a mathematical modelling framework to infer key pharmacokinetic parameters 28 29 and relate them to characteristics of the populations being treated. These characteristics 30 included age, weight, sex, dosage, infection status, and whether patients had received a fatty 31 meal prior to treatment or other drugs alongside albendazole. Our results highlight a number 32 of factors systematically associated with albendazole pharmacokinetic variation including 33 age, existing parasitic infection and receipt of a fatty meal. These factors impact different aspects of the drug's pharmacokinetic profile. Whilst age is significantly associated with 34 35 albendazole sulfoxide half-life, receipt of a fatty meal prior to treatment was associated with 36 increased albendazole bioavailability (and by extension, peak blood concentration and total 37 drug exposure following the dose). Parasitic infection (particularly echinococcosis and 38 neurocysticercosis) was associated with altered pharmacokinetic parameters, with infected 39 populations displaying distinct characteristics to uninfected ones.

## 40 **Conclusions/Significance**

These results highlight the extensive inter-individual variation that characterises albendazole
pharmacokinetics and provides insight into some of the factors associated with this variation.

43 Key-Words: Albendazole, Albendazole sulphoxide, Single-dose, Pharmacokinetics,
44 Systematic review, Modelling, Inter-individual variation

### C. Whittaker et al.

#### Albendazole Pharmacokinetics 3

## 46 Author Summary

Albendazole is a broad-spectrum anti-parasitic medication widely used in the treatment of a 47 48 variety of parasitic worm infections. Previous studies have demonstrated significant variation in the pharmacokinetics of albendazole (and its pharmacologically active metabolite 49 50 albendazole sulfoxide), leading to substantial inter-individual variability in blood plasma 51 concentrations following a dose of the drug being given. This variation is thought to have 52 important consequences for treatment success but our understanding of the factors driving this variation remain incomplete. In this study, we carried out a systematic review to identify 53 54 references with data on albendazole and albendazole sulfoxide concentrations in the blood 55 following a single oral dose. We then fitted a mathematical model of albendazole pharmacokinetics to these data to infer key pharmacokinetic parameters and relate them to 56 57 characteristics of the populations being treated. We found that receipt of a fatty meal prior to 58 treatment was associated with increased albendazole bioavailability, that the half-life of albendazole sulfoxide in the blood varied significantly with age, and that both echinococcosis 59 60 and neurocysticercosis were associated with altered pharmacokinetic profiles compared to 61 healthy individuals. Our work provides insight into some of the factors systematically 62 associated with variation in albendazole pharmacokinetics.

#### C. Whittaker et al.

#### Albendazole Pharmacokinetics 4

## 64 Introduction

65 Albendazole is a broad-spectrum medication used widely in the treatment of a variety of parasitic 66 worm infections. This includes usage in a clinical context, where multiple-dose regimens are used to 67 treat infections with the larval stages of *Taenia solium* ((neuro-)cysticercosis) [1] or of *Echinococcus* 68 spp. (principally cystic and alveolar echinococcosis due to, respectively, E. granulosus and 69 E. multilocularis) [2]. It has also been used extensively in neglected tropical disease (NTD) 70 programmatic contexts, for which albendazole is being/has been delivered (as a single-dose treatment) 71 to communities in mass drug administration (MDA) campaigns against soil-transmitted helminthiases 72 [3] (STHs, due to Ascaris lumbricoides, Trichuris trichiura, Necator americanus and/or Ancylostoma 73 *duodenale*), and delivered alone [4] or alongside ivermectin and/or diethylcarbamazine [5,6]) against 74 lymphatic filariasis [7] (LF, due to Wuchereria bancrofti or Brugia malayi). In addition, albendazole 75 has also been offered to individuals with loiasis [8,9], frequently those whose Loa loa microfilarial 76 densities are high enough to preclude safe treatment with microfilaricidal anthelmintics [10,11] (such 77 as diethylcarbamazine or ivermectin [12]).

Whilst the therapeutic efficacy of albendazole has been established for a wide array of helminth 78 79 parasites, the drug's pharmacokinetics (and those of its pharmacologically-active metabolite, 80 albendazole sulfoxide) are characterised by extensive inter- and intra-individual variation. This 81 variation has been consistently observed across a wide range of studies (see [13] for a review and its 82 implications for treatment), and is typically attributed to the drug's limited solubility in the 83 gastrointestinal tract and extensive first-pass metabolism by the liver (responsible for rapid conversion 84 of albendazole to albendazole sulfoxide). This variation is thought to contribute to the failure of cure 85 in some treated patients – whilst some require only one course of treatment, others require multiple 86 rounds and, in a limited number of instances, treatment failure has been observed [13–15]. This 87 variation in outcomes observed in clinical settings has also been seen in field studies, where highly 88 variable impact of the drug on STH infections have been observed depending on the setting [16]. For 89 example, the average reduction in faecal egg reduction rates for treated hookworm infections varied 90 from 53% to 95% across different communities in Ghana [17] (though note that such observations

#### C. Whittaker et al.

#### Albendazole Pharmacokinetics 5

91 might also be driven by variation between settings in the prevalence of different STH species which

are thought to show variable responses to albendazole treatment [18]).

93 A number of factors are deemed to underlie this variation in pharmacokinetic dynamics. Several 94 studies have examined the influence of different drivers, including sex [19], co-administered drugs 95 [20,21], delivery of albendazole alongside a fatty meal [22,23] and infection status [24,25] on the 96 pharmacokinetic profile of albendazole and/or albendazole sulfoxide. However, these studies typically 97 only analyse a single factor, and therefore a systematic understanding of the comparative impact of 98 different factors on albendazole's pharmacokinetics remains outstanding. Given albendazole's 99 widespread usage in NTD programmatic contexts, insight into mechanisms that influence the 100 pharmacokinetic profile of albendazole could have significant public health relevance.

101 Motivated by this, we conducted a systematic review of the literature to identify references containing 102 temporally disaggregated information on albendazole and/or albendazole sulfoxide concentrations in 103 the blood following treatment with a single oral dose (the typical regimen used in NTD programmatic 104 contexts). To these data, we fitted a mathematical model of albendazole and albendazole sulfoxide's 105 dynamics in the blood following receipt of the dose that captures key phenomena associated with the 106 drug's metabolism. These include albendazole's extensive first-pass metabolism [26] and its 107 established low bioavailability [27]. We fitted this model to data collated as part of the systematic 108 review to infer key pharmacokinetic parameters, including albendazole bioavailability, albendazole 109 sulfoxide half-life, peak albendazole concentration in the blood ( $C_{Max}$ ) and the total drug exposure 110 across time (commonly described as the area under the curve or AUC). We then related these 111 parameter estimates to characteristics of the patient populations being treated and the treatment 112 regimen received.

### 113 Methods

### 114 Systematic review of albendazole pharmacokinetic literature

Web of Science and PubMed databases were searched on 4<sup>th</sup> July 2019 with no limitations on date
range using the keywords "albendazole" AND (treatment\* OR dose\* OR pharma\* OR "half-life" OR

#### C. Whittaker et al.

#### Albendazole Pharmacokinetics 6

117 "half life") in order to identify references containing temporally disaggregated data detailing the 118 concentration of albendazole and/or albendazole sulfoxide in the blood following treatment with a 119 single dose of the drug. A total of 5690 unique records were identified through this search process, 120 with 206 records retained for full text evaluation following Title and Abstract screening (Fig 1). 121 Studies lacking the required information on blood concentration levels over time, that had been 122 carried out in vitro or in non-human subjects, or were not in English were subsequently excluded. 123 Following this, a total of 32 references were included, yielding 92 time-series describing the evolution 124 of blood concentrations of albendazole and/or albendazole sulfoxide following treatment with a single 125 dose. Fifteen time-series contained information on both albendazole and albendazole sulfoxide levels; 126 and 77 contained information on albendazole sulfoxide levels only. Eighty-four of these time-series 127 were studies in which only blood drug concentrations following a single oral dose of albendazole 128 were presented; and eight were studies in which measured blood drug concentrations were presented 129 that spanned a course of multiple doses, but that contained information on drug blood concentration 130 levels immediately following the first dose. For these eight time-series, we extracted data following 131 receipt of the first dose up until receipt of the second dose. For each time-series, we also extracted the 132 data describing evolution of albendazole/albendazole sulfoxide levels over time, as well as an array of 133 metadata. These included characteristics of the treatment regimen (dose, fasting state, co-administered 134 drugs), as well as information and metadata on the patients receiving treatment (sex, age, infection 135 status and weight). In the majority of instances, presented data were reported for a population of 136 patients rather than individuals. In these instances, population averages for factors such as age, 137 weight, etc., were extracted. A full list of these references, as well as further information about each 138 study and how the data were extracted are available in Supplementary S1 File, S1 Text: Data

139 Extraction, Collation and Initial Processing.

140 Fig 1: PRISMA diagram illustrating the systematic review workflow. Web of Science and 141 PubMed were searched on 4<sup>th</sup> July 2019 using the keywords albendazole AND (treatment\* OR dose\* 142 OR pharma\* OR "half-life" OR "half life"). This produced a total of 5690 results after duplicate 143 removal, of which 206 were retained for full text screening. 175 of the retained articles were 144 subsequently excluded based on pre-defined exclusion criteria, yielding 32 studies containing 145 temporally disaggregated data on albendazole blood concentrations following treatment with a single

#### C. Whittaker et al.

dose; these 32 references contained a total of 92 time-series measuring albendazole and/oralbendazole sulfoxide blood concentrations over time in different populations.

148

### 149 Mathematical model construction and fitting

150 We developed a model describing the evolution of albendazole and albendazole sulfoxide 151 concentrations in the blood following receipt of a single oral dose of the drug, based on a series of 152 linked ordinary differential equations (ODEs) of albendazole and its metabolite albendazole sulfoxide 153 (Fig 2). The model incorporates a number of pharmacokinetic phenomena relevant to albendazole, 154 including its well-established, limited bioavailability (thought to be a product of its poor solubility 155 along the gastrointestinal tract [27]) and the extensive first-pass metabolism of albendazole to 156 albendazole sulfoxide known to occur in the liver [26]. This model was fitted individually to each of 157 the 92 collated time-series within a Bayesian framework, utilising an adaptive Metropolis-Hastings 158 based Markov Chain Monte Carlo (MCMC) sampling scheme for parameter inference. Uninformative 159 priors were used for each of the parameters being subsequently related to the collected metadata. For 160 each dataset, a total of 25,000 iterations were run, with the first 5,000 discarded as burn in, leaving 161 20,000 samples available for parameter inference – the median value based on these samples was then 162 used as an input into the multiple linear regression (described below). Further information on the 163 exact formulation of the model and the fitting process is available in Supplementary S1 File, S2 Text: 164 Model Construction, Fitting and Inference.

165 Fig 2: Schematic representation of the model describing albendazole and albendazole sulfoxide 166 dynamics and pharmacokinetics. A compartmental model consisting of a series of linked ordinary 167 differential equations (ODEs) was developed to simulate the pharmacokinetics of albendazole and its 168 pharmacodynamically-active metabolite, albendazole sulfoxide, in the blood following a single oral 169 dose. (A) Schematic representation illustrating the model structure and the way in which the different 170 compartments are linked. (B) Overview of the ODEs governing the model, representing the amount of 171 albendazole in the gut and concentration of the drug (and its metabolite albendazole sulfoxide) in the 172 liver and systemic circulation. Note that the received dose is further scaled by a bioavailability 173 parameter not shown here (see S1 File, S2 Text subsection: Mathematical Model of Albendazole 174 and Albendazole Sulfoxide Dynamics for further details and full description of the model 175 equations).

176

## 177 Regression linking pharmacokinetic properties to patient characteristics

#### C. Whittaker et al.

#### Albendazole Pharmacokinetics 8

178 From the 92 fitted time-series, we extracted estimates of key pharmacokinetic parameters and 179 regressed them onto the collected metadata (describing aspects of the patient population and treatment 180 regimen received) to assess the influence of various factors on variation in albendazole and 181 albendazole sulfoxide's pharmacokinetics. The pharmacokinetic parameters were  $k_{AlbSO}$  (the half-life 182 of albendazole sulfoxide), the bioavailability of albendazole (the proportion of administered 183 albendazole absorbed from the gut into the blood),  $C_{Max}$  (the peak concentration of the drug in the 184 blood) and AUC ("area under the curve", reflecting the total exposure to the drug after administration 185 of the dose, calculated over a time-period of 50 hours).  $k_{AlbSO}$  and bioavailability are model 186 parameters directly estimated during the fitting process outlined above, and so for each time-series, 187 the median parameter estimate from each time-series was used in the regression. For  $C_{Max}$  and AUC, 188 in order to control for differences in dosages between studies (which would directly impact estimates 189 of these two quantities), we used the fitted model (and median parameter estimates) for each time-190 series to simulate and generate a hypothetical pharmacokinetic curve assuming a standardised dose of 191 400 mg. We then calculated  $C_{Max}$  and AUC from this hypothetical pharmacokinetic curve to give 192 estimates of the two parameters standardised by the dose received. We subsequently refer to these 193 quantities as  $C_{Max400}$  and  $AUC_{400}$ .

## 194 **Results**

#### 195 Systematic review results and study characteristics

196 A total of 32 references containing 92 time-series detailing the concentration of albendazole and/or 197 albendazole sulfoxide in the blood following treatment with a single dose of albendazole were 198 identified. Forty-four time-series were data for a single individual and 58 time-series described 199 average concentrations through time for a group of individuals (mean group size = 12.2, interquartile 200 range = 6-14), with the data comprising a total number of 629 individuals who had received a single 201 dose of albendazole. Of the 92 time-series identified, information on the sex of participants was 202 available for 67 time-series (37 from male participants, 24 including a mixture of males and females, 203 and 6 from female participants), with information on mean age and weight available for 79 and 69

#### C. Whittaker et al.

#### Albendazole Pharmacokinetics 9

204 time-series respectively. Sixteen time-series were from children under the age of 18. Information on 205 whether treatment was taken with a fatty meal was available for 75 time-series (29 received a fatty 206 meal, the remainder did not), whilst infection status was available for 91 time-series (48 were from 207 uninfected patient populations, 16 were from individuals with neurocysticercosis, 14 from individuals 208 with echinococcosis, 7 from individuals with onchocerciasis, 3 from individuals with lymphatic 209 filariasis, 2 from individuals with giardiasis and 1 from an individual with hookworm infection). The 210 median dose received was 400 mg (range 200 mg - 2205 mg). Co-administered drugs included 211 ivermectin (n=7), diethylcarbamazine (DEC, n=7), praziquantel (n=4), ritonavir (n=2), 212 dexamethasone (n=2), amoxicillin (n=1), gentamycin (n=1), metronidazole (n=1), ceftriaxone (n=1), 213 levamisole (n=1) and oxantel pamoate (n=1). Supplementary Table S1 in Supplementary S1 File 214 provides full details of each included study and time-series.

## 215 Pharmacokinetic modelling of albendazole and albendazole sulfoxide dynamics

216 To each of these collated time-series, we fitted a model describing the dynamics of albendazole and 217 albendazole sulfoxide concentrations in the blood following receipt of a single oral dose and before a 218 second dose in the case of treatment regimen using multiple doses (see Fig 2 for model structure and 219 formulation). This model was fitted individually to each time-series within a Bayesian MCMC-based 220 framework (see Supplementary Fig S1 in Supplementary S1 File for individual model fitting results 221 for each time-series). Our results highlighted significant variation in model estimates of key 222 pharmacokinetic parameters including  $k_{AlbSQ}$  (the half-life of albendazole sulfoxide), the 223 bioavailability of albendazole (i.e. proportion of administered albendazole absorbed from the gut into 224 the blood), C<sub>Max400</sub> (peak modelled concentration of albendazole sulfoxide in the blood following 225 receipt of a hypothetical 400 mg dose) and  $AUC_{400}$  (total modelled exposure to albendazole sulfoxide 226 following receipt of a hypothetical 400 mg dose of albendazole). Stratifying the modelled 227 pharmacokinetic profiles by various characteristics of the patient population suggested possible 228 systematic pharmacokinetic differences associated with patient- and treatment regimen-related 229 factors, although also extensive between-study variation in dynamics (Fig 3).

C. Whittaker et al.

230 Fig 3: Albendazole sulfoxide pharmacokinetic variability, stratified by patient and dosage 231 features. In all panels displayed above, each pale line represents the fitted model output for a single 232 time-series, with the darker lines representing the average of the time-series for a given category. 233 Factors explored were (A) Sex; (B) Feeding Status (according to whether groups had received the 234 single dose of albendazole alongside a fatty meal or not); (C) Dose (with time-series crudely 235 categorised into high/low strata based on whether the dose was higher or lower than 400 mg); (D) 236 Infection Status (defined as per the paper associated with each time-series as whether the patient 237 population were receiving treatment for a known infection or not); (E) Co-Administered Drugs (i.e. 238 whether albendazole was delivered alone or in tandem with other drugs); and (F) Age Group, defined 239 based on whether the average age of the patients was under 18 years old (children) or  $\geq 18$  years 240 (adults).

241

242 In order to explore these relationships more formally, we carried out a multiple linear regression 243 analysis to assess which of the factors in Fig 3 were statistically associated with differences in these 244 pharmacokinetic parameters. The results of this regression are displayed in Table 1. Receipt of a fatty 245 meal prior to treatment increased the bioavailability of albendazole by 38% on average (p<0.01) and 246 resulted in a significantly higher peak blood concentration ( $C_{Max400}$  being 353 mg/ml higher or 247 almost twice as high in individuals receiving a fatty meal on average, p<0.01). Receiving a fatty meal 248 prior to treatment was also associated with a 1.53-fold higher overall  $AUC_{400}$  than in fasted 249 individuals (p<0.01). Higher doses were associated with reduced albendazole bioavailability (with 250 bioavailablity reducing approximately 1% for each 100 mg increase in dosage, p=0.03). We did not 251 observe any significant differences in pharmacokinetic parameters that depended on sex.

252 Parasitic infection was associated with significant differences in pharmacokinetic parameters 253 compared to uninfected individuals. Whilst we did not detect any significant differences when 254 considering infection status as a binary indicator (i.e. whether an individual had a parasitic infection 255 or not), stratifying the infected population further by specific disease revealed significant associations 256 between particular diseases. There was a significant association between neurocysticercosis and 257 albendazole sulfoxide half-life (median 12 hours compared to 10.5 hours in uninfected individuals, 258 p=0.05); and significant effects of echinococcosis on bioavailability (increased by 14% in infected 259 compared to uninfected individuals, p<0.01) and  $C_{Max400}$  and  $AUC_{400}$  (increased by 2.7 and 4.0 fold 260 respectively, p<0.01 in both instances). We did not observe any significant association between 261 onchocerciasis and the considered pharmacokinetic parameters.

#### C. Whittaker et al.

#### Albendazole Pharmacokinetics 11

262 As a sensitivity analysis, we repeated the analyses described above controlling for the dose of 263 albendazole received per kilogram of body weight (available only for a subset of the time-series due 264 to a lack of complete information about participants' weight), rather than the raw amount (in mg, not 265 standardised by body weight) given to an individual. All significant associations described above 266 were retained when conducting this subset sensitivity analysis (see Supplementary S2 Table in 267 Supplementary File S1). Additionally, we observed a difference between age groups in the modelled 268 estimates of  $k_{AlbSO}$ , with the median half-life of albendazole sulfoxide at 12.4 hours in adults 269 compared to only 8.04 hours in children under the age of 18 years (p<0.01).

We did not detect a significant effect of co-administered drugs on albendazole's pharmacokinetics, though it is important to note that the heterogeneous array of drugs co-administered across the collated dataset, and the comparative paucity of time-series featuring each of the drugs precluded a stratified analysis of each drug individually (as was possible with disease status). This lack of data necessitated combining them into the binary category or yes/no co-administration. The corollary of this is that these analyses were not powered to reliably detect drug-drug interactions with albendazole (which are well documented in the literature).



Figure 1: PRISMA diagram illustrating the systematic review workflow. Web of Science and 282 PubMed were searched on 4<sup>th</sup> July 2019 using the keywords albendazole AND (treatment\* OR dose\* 283 284 OR pharma\* OR "half-life" OR "half life"). This produced a total of 5690 results after duplicate removal, of which 206 were retained for full text screening. 175 of the retained articles were 285 286 subsequently excluded based on pre-defined exclusion criteria, yielding 32 studies containing 287 temporally disaggregated data on albendazole blood concentrations following treatment with a single 288 dose; these 32 references contained a total of 92 time-series measuring albendazole and/or 289 albendazole sulfoxide blood concentrations over time in different populations.

290



300

301 Figure 2: Schematic representation of the model describing albendazole and albendazole 302 sulfoxide dynamics and pharmacokinetics. A compartmental model consisting of a series of linked 303 ordinary differential equations (ODEs) was developed to simulate the pharmacokinetics of 304 albendazole and its pharmacodynamically-active metabolite, albendazole sulfoxide, in the blood 305 following a single oral dose. (A) Schematic illustrating the model structure and the way in which the 306 different compartments are linked. (B) Overview of the ODEs governing the model, representing the 307 amount of albendazole in the gut and concentration of the drug (and its metabolite albendazole 308 sulfoxide) in the liver and systemic circulation. Note that the received dose is further scaled by a 309 bioavailablity parameter not shown here – see Supplementary Information Section "Mathematical 310 Model of Albendazole and Albendazole Sulfoxide Dynamics" for further details and full 311 description of the model equations.



318

319 Figure 3: Albendazole sulfoxide pharmacokinetic variability, stratified by patient and dosage 320 features. In all panels displayed above, each pale line represents the fitted model output for a single 321 time-series, with the darker lines representing the average of the time-series for a given category. 322 Factors explored were (A) Sex; (B) Feeding Status (according to whether groups had received the 323 single dose of albendazole alongside a fatty meal or not); (C) Dose (with time-series crudely 324 categorised into high/low strata based on whether the dose was higher than 400 mg); (D) Infection 325 Status (defined as per the paper associated with each time-series as whether the patient population 326 were receiving treatment for a known infection or not); (E) Co-Administered Drugs (i.e. whether 327 albendazole was delivered alone or in tandem with other drugs); and (F) Age Group, defined based on 328 whether the average age of the patients was under 18 years old (children) or ≥18 years (adults).

	C. Whittaker et al.	Albendazole Pharmacokinetics 15
330		
331		
332		
333		
334		

335

## **Table 1: Regression outputs relating pharmacokinetic properties to characteristics.** Inferred

337 parameters from the fitted pharmacokinetic curves, specifically albendazole bioavailability,

albendazole sulfoxide half-life, AUC and  $C_{Max}$  were regressed onto various patient population

demographic and treatment metadata.

	Bioavailability	AlbSO half-life	AUC (for standardised 400 mg dose)	<i>C<sub>Max</sub></i> (for standardised 400 mg dose)
Sex	p=0.25	p=0.90	p=0.44	p=0.15
( <b>Ref</b> = male)				
Fatty meal	p=0.001	p=0.93	p=0.01	p<0.001
	(+14%)		(+6141)	(+330)
Age group	p=0.67	p=0.19	p=0.12	p=0.95
$(\mathbf{Ref} = \mathbf{adults})$				
Dose (mg)	p=0.03	p=0.19	p=0.30	p=0.10
	(-1.1% per 100 mg			
	increase)			
Parasitic infection	p=0.41	p=0.10	p=0.46	p=0.95
( <b>Ref = none</b> )				
➔ Onchocerciasis	p=0.09	p=0.48	p=0.51	p=0.08
➔ Echinococcosis	p=0.04	p=0.15	p<0.001	p<0.001
	(+14%)		(+15604)	(+538)
➔ Neurocysticercosis	p=0.74	p=0.05	p=0.32	p=0.14
		(-1.5 hours)		
Co-administered drugs	p=0.09	p=0.48	p=0.58	p=0.27
( <b>Ref = none</b> )				

340

341

#### C. Whittaker et al.

#### Albendazole Pharmacokinetics 16

## 343 **Discussion**

344 Despite widespread usage, significant uncertainty surrounds the factors underlying variation in the 345 pharmacokinetics of albendazole. Whilst other studies have previously examined these factors 346 individually (e.g. [23,28-31] amongst others), a systematic analysis of different factors together 347 remained outstanding. Integrating the results of a systematic review of the literature with a 348 mathematical model of albendazole/albendazole sulfoxide dynamics, our work highlights the 349 extensive inter-individual pharmacokinetic variation in albendazole's dynamics, and the impact that a 350 number of different factors has in shaping the pharmacokinetic profile of the drug (and its metabolite) 351 in the blood following receipt of a single oral dose. Importantly, our results suggest that these 352 different factors influence different pharmacokinetic parameters, and hence alter different aspects of 353 the pharmacokinetic profile of the drug in the blood.

354 In-keeping with previous work [22,23,32–34], consumption of a fatty meal prior to receiving the dose 355 was associated with increased bioavailability of albendazole, increasing the amount absorbed into the 356 body (and concomitantly elevating the AUC and  $C_{Max}$  values achieved), a phenomenon thought to be 357 attributed to changes in the drug's solubility (previously shown to be the rate-limiting step in 358 albendazole's bioavailablity and absorption [27]) when delivered alongside a fatty meal [34]. Whilst 359 prior results from the literature have suggested (modest) differences between men and women in 360 albendazole's pharmacokinetics (specifically with regards to the AUC and  $C_{Max}$  [19]), we did not 361 observe any statistically significant differences here. However, important caveats to our results are 362 that the lack of individual data in many cases precluded examination of men and women separately. 363 Therefore, we constructed a crude proxy for comparison (between men and groups in which the 364 population comprised mixtures of men and women), which may not have been powered to detect the 365 (minor) differences previously reported [19]. We observed a small but significant effect of the dose of 366 albendazole received on the bioavailability of the drug, with bioavailability decreasing as the dose 367 increased. This is consistent with the well-described induction by albendazole of enzymes responsible 368 for its own metabolism [35]. Together, our results also suggest that different factors impact different 369 pharmacokinetic properties of albendazole and albendazole sulfoxide. For example, whilst receipt of a

#### C. Whittaker et al.

370 fatty meal was associated with increases to bioavailability, *AUC* and  $C_{Max}$ , age was significantly 371 associated with albendazole sulfoxide half-life (when controlling for dosage per kilogram of body 372 weight).

373 Perhaps most interestingly, our analyses suggested significant effects of parasitic infection on 374 albendazole pharmacokinetics, with the exact impact dependent on the infection being considered. 375 Previous work in sheep has highlighted that gastrointestinal nematode infection can influence the 376 kinetics of albendazole and albendazole sulfoxide, leading to increased AUC values [36]. Other work 377 has noted increased rates of transformation from albendazole to albendazole sulfoxide in infected 378 compared to uninfected sheep [37], though this has been inconsistently observed and the exact 379 influence (or lack thereof) likely depends on the particular infecting parasite [38]. Work in humans 380 has suggested that the precise impact of infection depends on the interaction between the drug 381 (particularly its absorption and elimination) and the infecting parasite's impact on the host. For 382 example, whilst recent work comparing the pharmacokinetics of albendazole in uninfected and 383 Wuchereria bancrofti-infected adults showed no differences [24], previous work exploring 384 albendazole kinetics in patients with echinococcosis demonstrated delayed absorption and impaired 385 elimination of the drug (with this latter effect contributing to increases in the AUC of albendazole 386 sulfoxide, particularly in patients with hepatic obstruction due to the disease) [39]. In-keeping with 387 these results, we observed a significant effect of echinococcosis on albendazole's pharmacokinetic 388 parameters, with infection associated with increases to the bioavailability,  $C_{Max}$  and AUC of the drug. By contrast, we observed no significant effect of onchocerciasis on albendazole's pharmacokinetics. 389 390 For neurocysticercosis, we observed alterations to the apparent half-life of albendazole sulfoxide. 391 However, these results should be interpreted with caution. Sample sizes for each of the individual 392 infections were small; for example, the largest was for echinococcosis with 14 time-series drawn from 393 a total of four studies. The estimates presented here are therefore uncertain, and it is possible that 394 study-specific variation not accounted for might explain the observed results. Relatedly, whilst we 395 attempted to control for co-administered drugs, our ability to do this was limited (see below). It is,

#### C. Whittaker et al.

#### Albendazole Pharmacokinetics 18

396 therefore, possible that the results presented here might be confounded by the receipt of treatment for 397 an infection that is not described in the reference.

398 There are a number of limitations to the analyses presented here. Firstly, and perhaps most notably, 399 the available data in the literature were highly heterogeneous, involving a diversity of treatment 400 regimens (i.e. other co-administered drugs) and patients (i.e. characteristics), with data available at 401 different levels of aggregation (i.e. individual vs. average profiles). This constraint limits the 402 statistical power of our analyses to characterise the effects of different individual drugs on 403 albendazole's pharmacokinetics. Whilst our binary indicator for co-administered drugs was not found 404 to be significantly associated with any of the pharmacokinetic parameters explored here, numerous 405 interactions between albendazole and other drugs such as cimetidine [20], azithromycin [40] and 406 various anti-epileptic drugs [41] are well-documented in the literature. It is also important to note the 407 overall paucity of available data upon which the inferences presented here are based. Whilst 408 albendazole sulfoxide data were available for all 92 time-series considered here, data on albendazole's 409 pharmacokinetics was only available for 15 time-series; and in no cases was comparable information 410 relevant to the drug's metabolism (such as liver function) available.

411 In addition to these constraints posed by population-level data, the results presented here are limited 412 in that they only describe the pharmacokinetic dynamics following treatment with a single dose of 413 albendazole. This holds programmatic relevance given usage of albendazole in MDA programmes 414 targeting STH [42] and/or LF [43] amongst others but other treatment regimen exist, most notably the 415 use of albendazole in dedicated clinical settings to treat individuals for diseases such as cysticercosis 416 and echinococcosis. These regimens typically utilise multiple doses delivered over consecutive days. 417 Previous results have indicated that albendazole appears to induce its own metabolism through 418 induction of key enzymes in the liver [25], and that multiple doses given over sequential days can lead 419 to changes in pharmacokinetic properties over the course of multiple dose regimen; specifically, 420 reductions in the maximum blood concentrations of albendazole sulfoxide reached following each 421 dose [44]. However, the magnitude of this effect and the frequency of dosing required to elicit 422 pharmacologically-relevant reductions in blood concentrations remain far from clear and have, to

#### C. Whittaker et al.

429

#### Albendazole Pharmacokinetics 19

date, been addressed in only a limited number of studies. Exploration of this phenomenon and its consequences for anthelmintic treatment regimens using multiple doses of the drug would require both further clinical research and an extension of the mathematical model developed here, and likely represents an instructive avenue of future investigation. Similarly, extensions of the model to include infrequent but reported pharmacokinetic phenomena associated with albendazole treatment, such as biphasic pharmacokinetic profiles (thought possibly to be a product of inter-individual variation in

frequency of gastric emptying affecting release of ingested albendazole into the gut, as well as other

430 related characteristics [45]), would also likely provide new insight.

431 The availability of studies explicitly exploring the pharmacokinetics of drugs used to treat NTDs is 432 limited [46]. Despite the limitations described above, our work begins to address this gap for 433 albendazole. It suggests potential useful avenues for improvements to programmatic delivery of 434 albendazole, and perhaps more importantly, highlights the existence of significant inter-individual 435 variation in albendazole pharmacokinetics. Whilst we provide insight into some of the factors 436 underlying this variation, further quantification and exploration will be essential. This is particularly 437 crucial for understanding and interpreting the results of studies exploring programmatic usage of the 438 drug to treat parasitic infections. Having an understanding of the degree of inter-individual variation 439 will be vital for establishing whether observed sub-optimal responses to the drug are due to parasitic 440 factors (e.g. possible resistance potentially developed through cumulative exposure to treatment over 441 multiple rounds [47]) or, instead, simply reflect a high degree of variation between individuals in total 442 exposure to the drug (and hence anti-parasitic effect) that follows ingestion of the same oral dose. 443 Indeed, previous work has demonstrated a high degree of community-level variation in the impacts of 444 ivermectin distribution campaigns to treat onchocerciasis in Ghana, even across communities 445 characterised by similar histories of ivermectin exposure [48], highlighting the need to understand 446 patterns of variation in drug responses (both at the individual and community level) if the underlying 447 causes are to be accurately determined. Together, these results support and underscore recent calls 448 highlighting the need for the collection, collation and analysis of individual participant data (IPD) to 449 generate robust evidence on efficacy and safety of anti-parasitic treatment regimens [49]. Given the

#### C. Whittaker et al. Albendazole Pharmacokinetics 20

450	increasing frequency with which albendazole is being utilised as part of community-based MDA
451	programmes aimed at controlling a wide array of parasitic infections and NTDs, such an
452	understanding would hold important public health relevance.

**Data and Code Availability:** All data collated as part of this study, as well as the analytical code used to generate the analyses reported in the Main Text and Supplementary File can be found at the following link: <u>https://github.com/cwhittaker1000/albendazole\_pk</u>.

456 Acknowledgements: We deeply thank Dr Annette C. Kuesel for her hugely insightful and helpful

457 comments on earlier versions of this manuscript, which have materially improved and contributed to458 the work now presented here.

## 459 Funding Statement:

460 C.W. and M.G.B. acknowledge funding from the Medical Research Council (MRC) Centre for Global

461 Infectious Disease Analysis (MR/R015600/1), jointly funded by the UK MRC and the UK Foreign,

462 Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is
463 also part of the European and Developing Countries Clinical Trials Partnership (EDCTP2)
464 programme supported by the European Union.

## 465 Authors Contributions:

Charlie Whittaker: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology,
Software, Visualization, Writing – Original Draft Preparation; Cédric B. Chesnais: Resources,
Writing – Review & Editing; Sébastien D.S. Pion: Writing – Review & Editing; Joseph Kamgno:
Writing – Review & Editing; Martin Walker: Resources, Writing – Review & Editing; MariaGloria Basáñez: Conceptualization, Funding Acquisition, Project Administration, Resources,
Supervision, Writing – Review & Editing; Michel Boussinesq: Conceptualization, Project
Administration, Resources, Supervision, Writing – Review & Editing.

C. Whittaker et al.	Albendazole Pharmacokinetics 21

474	Supplementary	S1 File:	Additional	Methods and	<b>Results</b>
4/4	Supplementary	SI File:	Additional	Methods and	i Kesu

- 475 S1 Text: Data Extraction, Collation and Initial Processing
- 476 Systematic Review References & Associated Metadata
- 477 S1 Table: Studies collated through the systematic review and their associated metadata
- 478 S2 Text: Model Construction, Fitting and Inference
- 479 Mathematical Model of Albendazole and Albendazole Sulfoxide Dynamics
- 480 Model Fitting and Inferential Framework
- 481 Pharmacokinetic Parameter Estimation and Multiple Linear Regression Modelling
- 482 S1 Figure: Results of model fitting and calibration to data collated through the systematic
  483 review.
- 484 S2 Table: Multiple linear regression results relating pharmacokinetic properties to study
- characteristics when controlling for dosage per kilogram of body weight instead of raw dosage
- 486 amount in milligrams
- 487 Supplementary References

## 489 **References**

490	1.	Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews H, et al. Effects of albendazole
491		treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry.
492		2008;79: 1050–1055. doi:10.1136/jnnp.2008.144899

- 493 2. Teggi A, Lastilla MG, De Rosa F. Therapy of human hydatid disease with mebendazole and
  494 albendazole. Antimicrob Agents Chemother. 1993;37: 1679–1684. doi:10.1128/AAC.37.8.1679
- Vlaminck J, Cools P, Albonico M, Ame S, Ayana M, Cringoli G, et al. Therapeutic efficacy of
  albendazole against soil-transmitted helminthiasis in children measured by five diagnostic
  methods. PLoS Negl Trop Dis. 2019;13: e0007471. doi:10.1371/journal.pntd.0007471
- 4. Pion SDS, Chesnais CB, Weil GJ, Fischer PU, Missamou F, Boussinesq M. Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo. Lancet Infect Dis. 2017;17: 763–769. doi:10.1016/S1473-3099(17)30175-5
- 502 5. Macfarlane CL, Budhathoki SS, Johnson S, Richardson M, Garner P. Albendazole alone or in
  503 combination with microfilaricidal drugs for lymphatic filariasis. Cochrane Database Syst Rev.
  504 2019;1: CD003753. doi: 10.1002/14651858.CD003753.pub4
- 505 Dubray CL, Sircar AD, Beau de Rochars VM, Bogus J, Direny AN, Ernest JR, et al. Safety and 6. 506 efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug 507 administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-508 randomized, community study. PLoS Negl Trop Dis. 2020;14: e0008298. 509 doi:10.1371/JOURNAL.PNTD.0008298
- 510 7. Simonsen PE, Pedersen EM, Rwegoshora RT, Malecela MN, Derua YA, Magesa SM.
  511 Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with
  512 ivermectin and albendazole on infection and transmission. PLoS Negl Trop Dis. 2010;4: e696.
  513 doi:10.1371/journal.pntd.0000696
- Klion AD, Massougbodji A, Horton J, Ekoué S, Lanmasso T, Ahouissou NL, et al. Albendazole
   in human loiasis: results of a double-blind, placebo-controlled trial. J Infect Dis. 1993;168: 202–
   206. doi:10.1093/infdis/168.1.202
- 517 9. Klion AD, Horton J, Nutman TB. Albendazole therapy for loiasis refractory to
  518 diethylcarbamazine treatment. Clin Infect Dis. 1999;29: 680–682.

C. Whittaker et al.	Albendazole Pharmacokinetics 23
---------------------	---------------------------------

- 519 10. Arrey-Agbor DB, Nana-Djeunga HC, Mogoung-Wafo AE, Mafo M, Danwe C, Kamgno J. Case 520 report: Probable case of spontaneous encephalopathy due to loiasis and dramatic reduction of 521 Loa loa microfilariaemia with prolonged repeated courses of albendazole. Am J Trop Med Hyg. 522 2018;99: 112–115. 523 11. Kamgno J, Nguipdop-Djomo P, Gounoue R, Téjiokem M, Kuesel AC. Effect of two or six doses 524 800 mg of albendazole every two months on Loa loa microfilaraemia: A double blind, 525 randomized, placebo-controlled trial. PLoS Negl Trop Dis. 2016;10: e0004492. 526 12. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. 527 Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for 528 Loa loa infection. Lancet. 1997;350: 18–22. doi:10.1016/S0140-6736(96)11094-1 529 13. Jung-Cook H. Pharmacokinetic variability of anthelmintics: implications for the treatment of 530 neurocysticercosis. Expert Rev Clin Pharmacol. 2012;5: 21-30. doi:10.1586/ECP.11.72 531 14. Del Brutto OH. Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging 532 analysis of 17 patients. J Neurol Neurosurg Psychiatry. 1997;62: 659–661. 533 doi:10.1136/jnnp.62.6.659 15. García HH, Evans CAW, Nash TE, Takayanagui OM, White AC Jr, Botero D, et al. Current
- 534 535 consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15: 747-756. 536 doi:10.1128/CMR.15.4.747-756.2002
- 537 16. Mrus J, Baeten B, Engelen M, Silber SA. Efficacy of single-dose 500 mg mebendazole in soil-538 transmitted helminth infections: а review. J Helminthol. 2018:92: 269-278.539 doi:10.1017/S0022149X17000426
- 540 17. Humphries D, Nguyen S, Kumar S, Quagraine JE, Otchere J, Harrison LM, et al. Effectiveness 541 of albendazole for hookworm varies widely by community and correlates with nutritional 542 factors: A cross-sectional study of school-age children in Ghana. Am J Trop Med Hyg. 2017;96: 543 347-354. doi:10.4269/ajtmh.16-0682
- 544 18. Basáñez M-G, French MD, Walker M, Churcher TS. Paradigm lost: how parasite control may 545 alter pattern and process in human helminthiases. Trends Parasitol. 2012;28: 161-171. 546 doi:10.1016/J.PT.2012.02.004
- 547 19. Mirfazaelian A, Dadashzadeh S, Rouini MR. Effect of gender in the disposition of albendazole 548 metabolites in humans. Eur J Clin Pharmacol. 2002;58: 403-408. doi:10.1007/s00228-002-0488-8
- 549

C. Whittaker et al. Albendazole Pharmacokinetics 24

550 20. Schipper HG, Nagy J, Van Boxtel CJ, Koopmans RP, Kager PA, Butter JJ. Effect of dose 551 increase or cimetidine co-administration on albendazole bioavailability. Am J Trop Med Hyg. 552 2000;63: 270-273. doi:10.4269/ajtmh.2000.63.270 553 21. Awadzi K, Edwards G, Duke BOL, Opoku NO, Attah SK, Addy ET, et al. The co-administration 554 of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca 555 volvulus. Ann Trop Med Parasitol. 2003;97: 165–178. doi:10.1179/000349803235001697 556 22. Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with 557 fatty meal. Eur J Clin Pharmacol. 1988;34: 315-317. doi: 10.1007/BF00540964 558 23. Mares SS, Jung CH, López AT, González-Esquivel DF. Influence of a Mexican diet on the 559 bioavailability of albendazole. Basic Clin Pharmacol Toxicol. 2005;97: 122-124. 560 doi:10.1111/j.1742-7843.2005.pto\_172.x 561 24. Edi C, Bjerum CM, Ouattara AF, Chhonker YS, Penali LK, Méité A, et al. Pharmacokinetics, 562 safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and 563 ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire. PLoS 564 Negl Trop Dis. 2019;13: e0007325. doi:10.1371/journal.pntd.0007325 565 25. Steiger U, Cotting J, Reichen J. Albendazole treatment of echinococcosis in humans: effects on 566 microsomal metabolism and drug tolerance. Clin Pharmacol Ther. 1990;47: 347-353. 567 doi:10.1038/clpt.1990.38 568 26. Lawrenz A, Eglit S, Kroker R. The metabolism of albendazole in the isolated perfused intestine 569 of rats. Dtsch Tierarztl Wochenschr. 1992;99: 416-418. 570 27. Jung H, Medina L, García L, Fuentes I, Moreno-Esparza R. Absorption studies of albendazole 571 and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J 572 Pharm Pharmacol. 1998;50: 43-48. doi:10.1111/j.2042-7158.1998.tb03303.x 573 28. Jung H, Sánchez M, González-Astiazarán A, Martínez JM, Suástegui R, González-Esquivel DF. 574 Clinical pharmacokinetics of albendazole in children with neurocysticercosis. Am J Ther. 575 1997;4: 23-26. doi: 10.1097/00045391-199701000-00005 576 29. Pengsaa K, Na-Bangchang K, Limkittikul K, Kabkaew K, Lapphra K, Sirivichayakul C, et al. 577 Pharmacokinetic investigation of albendazole and praziquantel in Thai children infected with 578 Parasitol. Giardia intestinalis. Trop Med 2004;98: 349-357. Ann 579 doi:10.1179/000349804225003398

C. Whittaker et al. Albendazole Pharmacokinetics 25

- 30. Nagy J, Schipper HG, Koopmans RP, Butter JJ, Van Boxtel CJ, Kager PA. Effect of grapefruit
  juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg.
  2002;66: 260–263. doi:10.4269/ajtmh.2002.66.260
- 583 31. Mirfazaelian A, Rouini MR, Dadashzadeh S. Dose dependent pharmacokinetics of albendazole
  584 in human. Biopharm Drug Dispos. 2002;23: 379–383. doi:10.1002/bdd.327
- 585 32. Ochoa D, Saiz-Rodríguez M, González-Rojano E, Román M, Sánchez-Rojas S, Wojnicz A, et al. 586 High-fat breakfast increases bioavailability of albendazole compared to low-fat breakfast: 587 Single-dose study in healthy subjects. Front Pharmacol. 2021;12: 664465. 588 doi: 10.3389/fphar.2021.664465
- 33. Awadzi K, Hero M, Opoku NO, Büttner DW, Coventry PA, Prime MA, et al. The chemotherapy
  of onchocerciasis XVII. A clinical evaluation of albendazole in patients with onchocerciasis;
  effects of food and pretreatment with ivermectin on drug response and pharmacokinetics. Trop
  Med Parasitol. 1994;45: 203–208.
- 593 34. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62: 1481–1502.
   594 doi:10.2165/00003495-200262100-00005
- Souhaili-el Amri H, Fargetton X, Benoit E, Totis M, Batt AM. Inducing effect of albendazole on rat liver drug-metabolizing enzymes and metabolite pharmacokinetics. Toxicol Appl Pharmacol. 1988;92: 141–149. doi: 10.1016/0041-008x(88)90236-0
- 36. Alvarez LI, Sánchez SF, Lanusse CE. Modified plasma and abomasal disposition of albendazole
  in nematode-infected sheep. Vet Parasitol. 1997;69: 241–253. doi:10.1016/S03044017(96)01118-1
- 601 37. Skálová L, Krízová V, Cvilink V, Szotáková B, Storkánová L, Velík J, et al. Mouflon (Ovis 602 musimon) dicrocoeliosis: effects of parasitosis on the activities of biotransformation enzymes 603 and albendazole metabolism in liver. Vet Parasitol. 2007;146: 254-262. 604 doi:10.1016/j.vetpar.2007.02.026
- 38. McKellar QA, Jackson F, Coop RL, Baggot JD. Plasma profiles of albendazole metabolites after
  administration of netobimin and albendazole in sheep: effects of parasitism and age. Br Vet J.
  1993;149: 101–113. doi: 10.1016/S0007-1935(05)80213-1
- 608 39. Cotting J, Zeugin T, Steiger U, Reichen J. Albendazole kinetics in patients with echinococcosis:
  609 delayed absorption and impaired elimination in cholestasis. Eur J Clin Pharmacol. 1990;38: 605–
  610 608. doi: 10.1007/BF00278590

C. Whittaker et al.

40. Amsden GW, Gregory TB, Michalak CA, Glue P, Knirsch CA. Pharmacokinetics of
azithromycin and the combination of ivermectin and albendazole when administered alone and
concurrently in healthy volunteers. Am J Trop Med Hyg. 2007;76: 1153–1157.
doi:10.4269/ajtmh.2007.76.1153

- 41. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol.
  2006;61: 246–255. doi:10.1111/j.1365-2125.2005.02529.x
- Echazú A, Juarez M, Vargas PA, Cajal SP, Cimino RO, Heredia V, et al. Albendazole and
  ivermectin for the control of soil-transmitted helminths in an area with high prevalence of
  Strongyloides stercoralis and hookworm in northwestern Argentina: A community-based
  pragmatic study. PLoS Negl Trop Dis. 2017;11: e0006003. doi:10.1371/journal.pntd.0006003
- 43. Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, et al. The safety of doubleand triple-drug community mass drug administration for lymphatic filariasis: A multicenter,
  open-label, cluster-randomized study. PLoS Med. 2019;16: e1002839.
  doi:10.1371/journal.pmed.1002839
- 44. Hoaksey PE, Awadzi K, Ward SA, Coventry PA, Orme ML, Edwards G. Rapid and sensitive
  method for the determination of albendazole and albendazole sulphoxide in biological fluids. J
  chromatogr. 1991;566: 244–249. doi:10.1016/0378-4347(91)80131-U
- 45. Davies NM, Takemoto JK, Brocks DR, Yáñez JA. Multiple peaking phenomena in
  pharmacokinetic disposition. Clin Pharmacokinet. 2010;49: 351–377. doi:10.2165/11319320000000000-00000
- 46. Verrest L, Dorlo TPC. Lack of clinical pharmacokinetic studies to optimize the treatment of
  neglected tropical diseases: A systematic review. Clin Pharmacokinet. 2017;56: 583–606.
  doi:10.1007/s40262-016-0467-3
- 634 47. Walker M, Cools P, Albonico M, Ame SM, Ayana M, Dana D, et al. Individual responses to a 635 single oral dose of albendazole indicate reduced efficacy against soil-transmitted helminths in an 636 with PLoS Dis. 2021;15: e0009888. area high drug pressure. Negl Trop 637 doi:10.1371/JOURNAL.PNTD.0009888
- 638 48. Churcher TS, Pion SDS, Osei-Atweneboana MY, Prichard RK, Awadzi K, Boussinesq M, et al.
  639 Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. Proc Natl
  640 Acad Sci U S A. 2009;106: 16716–16721. doi:10.1073/PNAS.0906176106

C. Whittaker et al.	Albendazole Pharmacokinetics 27

- 641 49. Walker M, Freitas LT, Halder JB, Brack M, Keiser J, King CH, et al. Improving anthelmintic
- treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of
- 643 individual participant data. Wellcome Open Res. 2022;7: 5.
- 644 doi:10.12688/wellcomeopenres.17468.1